Insider Selling: Aura Biosciences (NASDAQ:AURA) Insider Sells $82,330.08 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Anthony Gibney sold 12,824 shares of Aura Biosciences stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $6.42, for a total value of $82,330.08. Following the transaction, the insider owned 265,354 shares of the company’s stock, valued at $1,703,572.68. This represents a 4.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Aura Biosciences Trading Up 0.5%

AURA opened at $6.34 on Friday. The stock’s fifty day simple moving average is $7.21 and its 200 day simple moving average is $6.33. Aura Biosciences, Inc. has a 1-year low of $4.73 and a 1-year high of $9.53. The stock has a market cap of $655.49 million, a PE ratio of -3.64 and a beta of 0.39.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.10). Equities analysts forecast that Aura Biosciences, Inc. will post -1.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AURA has been the topic of a number of research reports. Wall Street Zen upgraded shares of Aura Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. HC Wainwright raised their price objective on shares of Aura Biosciences from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Weiss Ratings upgraded Aura Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 12th. Finally, Leerink Partners set a $17.00 target price on Aura Biosciences in a research note on Tuesday, May 12th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aura Biosciences presently has an average rating of “Hold” and an average price target of $20.50.

Hedge Funds Weigh In On Aura Biosciences

Hedge funds have recently bought and sold shares of the business. Parallel Advisors LLC boosted its holdings in Aura Biosciences by 130.4% in the 1st quarter. Parallel Advisors LLC now owns 5,665 shares of the company’s stock valued at $38,000 after purchasing an additional 3,206 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Aura Biosciences by 49.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $40,000 after purchasing an additional 2,104 shares during the period. Water Island Capital LLC acquired a new stake in shares of Aura Biosciences in the third quarter valued at approximately $64,000. 49 Wealth Management LLC acquired a new stake in shares of Aura Biosciences in the third quarter valued at approximately $66,000. Finally, ProShare Advisors LLC bought a new stake in shares of Aura Biosciences in the fourth quarter valued at approximately $59,000. 96.75% of the stock is owned by institutional investors.

Aura Biosciences Company Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.